Clinical trial
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously…
NCT00179647 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00179647 |
|---|---|
| Title | Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma |
| Official title | A Multicenter, Single-Arm, Open-Label, Expanded Access Program for Lenalidomide With or Without Dexamethasone in Previously Treated Subjects With Multiple Myeloma |
| Lead sponsor | Celgene Corporation, Industry |
| Collaborators | Prologue Research International Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | lenalidomide, dexamethasone |
| Enrollment | 1,913 |
| Start date | Sep 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Sep 16, 2005 |
| Last update posted | Mar 16, 2010 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: